ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2017

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.

S P Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.